Search

Your search keyword '"Goldstein, Michaella"' showing total 290 results

Search Constraints

Start Over You searched for: Author "Goldstein, Michaella" Remove constraint Author: "Goldstein, Michaella"
290 results on '"Goldstein, Michaella"'

Search Results

2. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2

3. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials

4. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials

6. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

7. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

8. TENAYA and LUCERNE

9. Faricimab Treat-and-Extend for Diabetic Macular Edema

16. Incidence and risk factors of visual impairment in patients with angioid streaks and macular neovascularization

19. Ocular Behçet Disease—Clinical Manifestations, Treatments and Outcomes According to Age at Disease Onset

20. Retinal vascular occlusions in ocular Behçet disease – a comparative analysis

22. Incidence and Risk Factors of Visual Impairment in Patients with Angioid Streaks and Macular Neovascularization

23. Disciform Scar

27. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials

38. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

39. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

49. Prospective, Longitudinal Pilot Study

Catalog

Books, media, physical & digital resources